Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download report

State of the genomics industry 2025: From potential to practice

The genomics industry in 2025 is both accelerating and recalibrating. Sequencing is cheaper than ever, AI tools are maturing, and national biobanks have amassed genomic data from millions of individuals – fueling progress in discovery, diagnostics, and therapeutics. Nevertheless, clinical adoption is lagging. Gene therapy programs face renewed safety scrutiny, infrastructure gaps remain unresolved, and biotech funding is narrowing toward assets with immediate commercial paths.

This industry report brings together insight from industry experts, market data, and a synthesis of the year’s major events and scientific breakthroughs to make sense of a field at an inflection point. We explore:

📈 Market dynamics, mergers & acquisitions, and funding shifts

🧬  Breakthroughs in diagnostics, data, and therapeutics

📊 The growing role of AI, biobanks, and real-world data

📋 Persistent barriers in infrastructure, regulatory processes, access, and pricing

Download now to access the full report, expert commentary, and a roadmap for moving from potential to practice.

stategroup